Search

Your search keyword '"Hartkopf AD"' showing total 214 results

Search Constraints

Start Over You searched for: Author "Hartkopf AD" Remove constraint Author: "Hartkopf AD" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
214 results on '"Hartkopf AD"'

Search Results

1. Dormancy in breast cancer

2. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

3. Einfluss eines wöchentlichen Lebensqualitäts-Screenings auf die Therapiezufriedenheit unter (neo-)adjuvanter Chemotherapie beim primären Brustkrebs – erste Ergebnisse aus der ENABLE-Studie

4. ENABLE – innovative Versorgungskonzepte bei der Betreuung von Patientinnen mit Mammakarzinom

5. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

9. Nutzung eines molekularen Registers (PRAEGNANT) zur Patienten-Selektion und Biomarker-Analyse für die SHERBOC Studie

14. International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer : Results from the PADDY study

16. Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167)

17. Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study

18. Abstract OT1-11-02: PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167)

19. Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167)

20. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

21. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

22. Tablet-basierte Erhebung der gesundheitsbezogenen Lebensqualität bei adjuvantem und metastasiertem Brustkrebs: Akzeptanz und Reliabilität

25. Vergleich der Anzahl zirkulierender Tumorzellen mit dem Proliferationsmarker Ki-67 beim metastasierten Mammakarzinom

27. Unexpected malignant uterine pathology: incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease

29. Abstract P6-11-10: Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

30. Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry

32. Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry

33. Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort

35. Zur prognostischen Relevanz des CTC-Status bei Progress des metastasierten Mammakarzinoms

38. Prognostische Relevanz von CTC-Status und Kinetik bei erneutem Progress des metastasierten Mammakarzinoms

39. Reliabilität einer elektronischen Version des EORTC QLQ C-30-Fragebogens zur Messung der gesundheitsbezogenen Lebensqualität bei Brustkrebspatientinnen

40. Abstract P3-11-05: Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study

Catalog

Books, media, physical & digital resources